NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-RM-17-033 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-525 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-033 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-087 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-17-006 from the NIH Guide for Grants and Contracts. The funding opportunity announcement (FOA) will support development and pilot testing of assays, such as DNA repair capacity or mutation detection, that will facilitate the wider use of genome integrity investigation in epidemiological and population studies.
Funding Opportunity RFA-NS-17-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials.
Notice NOT-GM-17-010 from the NIH Guide for Grants and Contracts
Notice NOT-EY-17-007 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-523 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-522 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-086 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-035 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-18-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to design and implement research infrastructure that will enable the monitoring of cognitive abilities and age, state, context, or health condition-related changes in cognitive abilities on mobile devices. This effort will include the development (or support for development) of apps on the Android and iOS platforms, the validation of tests and items to be used on the two leading smartphone platforms in age groups ranging from 20 to 85, and the norming of successfully validated measures to nationally representative U.S. population samples that will also receive gold standard measures, including the NIH Toolbox for Assessment of Behavioral and Neurological Function. A goal of this project is to also support data collection efforts from participants enrolled in projects awarded through this FOA as well as other NIH-funded studies though FY2022, and enable the widespread sharing of both the collected data and the test instruments.
Funding Opportunity RFA-AR-18-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to publicize a competition for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide an outstanding environment for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Center investigators are expected to participate in important community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.
Notice NOT-AI-17-031 from the NIH Guide for Grants and Contracts
Notice NOT-AA-17-007 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-082 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-084 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-17-013 from the NIH Guide for Grants and Contracts. The Food and Drug Administration (FDA) is announcing the availability of cooperative agreement funds for the support of a Funding Opportunity Announcement (FOA) entitled "Academic Development of a Training Program for Good Laboratory Practices in High Containment Environments (U24).' In this FOA, FDA announces its intention to accept and consider a single source application for an award to the University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL) for the development and implementation of a certified, academic training course for instruction in Good Laboratory Practices (GLP) in a Biosafety Level (BSL) 4 High Containment Environment. FDA seeks to support an effort to design a robust, collaborative, and educational program using problem-based learning techniques designed to bring researchers and regulators together to educate each other on the challenges related to these issues and to identify solutions that are acceptable from both scientific and regulatory perspectives.
Funding Opportunity RFA-FD-17-014 from the NIH Guide for Grants and Contracts. The goals of this program are to support the development of the scientific infrastructure needed to plan and execute pediatric clinical trials through collaboration with stakeholders from academia, industry, parent/patient advocacy groups, and government agencies. The Global Pediatric Trial Network should be a coordinating resource for pediatric product development with sustainable global infrastructure to plan, start up, conduct, and close out pediatric clinical investigations. There should be an emphasis on operational efficiency and network sustainability with early, systematic, and integrative approaches to pediatric studies.